COVID-19 Therapeutics Accelerator Clinical Studies Proposal Portal
The Therapeutics Accelerator is committing funding to speed-up the response to the COVID-19 epidemic by playing a catalytic role in accelerating the evaluation of new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. The Therapeutics Accelerator is a collaborative effort committed to equitable access, including making products available and affordable in low-resource settings.
This portal is provided for researchers to propose clinical studies. The process begins with an eligibility quiz which, if passed, is followed by a screening questionnaire. The screening questionnaire is reviewed; resulting in either a request for additional information, deferring, or advancing. If the submission advances, then the submitter will be requested to complete a full proposal questionnaire. This will enable a rigorous and standardized review and subsequent discussion of a clinical trial to enhance the probability of having an informative and efficient study. While always true, ensuring informative and timely study outcomes is especially critical during a pandemic. As part of the full proposal, the submitter will also be asked to upload a study protocol, statistical analysis plan, and budget documents.
We have found the use of solid, publicly available evidence for effective estimates and other assumptions, simulating sample sizes, use of real-world evidence and accepted endpoints along with innovative design differentiates a study from its peers. We will all help bring safe therapies faster if the study shows plans for use of solid science and evidence that the outcomes can be used to influence policy.
COVID-19 Therapeutics Accelerator Clinical Studies Proposal Portal
COVID-19 Therapeutics Accelerator Clinical Studies Proposal Portal
The Therapeutics Accelerator is committing funding to speed-up the response to the COVID-19 epidemic by playing a catalytic role in accelerating the evaluation of new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. The Therapeutics Accelerator is a collaborative effort committed to equitable access, including making products available and affordable in low-resource settings.
This portal is provided for researchers to propose clinical studies. The process begins with an eligibility quiz which, if passed, is followed by a screening questionnaire. The screening questionnaire is reviewed; resulting in either a request for additional information, deferring, or advancing. If the submission advances, then the submitter will be requested to complete a full proposal questionnaire. This will enable a rigorous and standardized review and subsequent discussion of a clinical trial to enhance the probability of having an informative and efficient study. While always true, ensuring informative and timely study outcomes is especially critical during a pandemic. As part of the full proposal, the submitter will also be asked to upload a study protocol, statistical analysis plan, and budget documents.
We have found the use of solid, publicly available evidence for effective estimates and other assumptions, simulating sample sizes, use of real-world evidence and accepted endpoints along with innovative design differentiates a study from its peers. We will all help bring safe therapies faster if the study shows plans for use of solid science and evidence that the outcomes can be used to influence policy.